Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (HK:6990) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. successfully convened its 2023 Annual General Meeting, with shareholders overwhelmingly approving all resolutions, including the financial statements and reports for 2023, the financial budget for 2024, and the reappointment of KPMG as auditors. The company also confirmed the appointment of a new non-executive director and ratified amendments to its Articles of Association. These approvals reflect strong shareholder confidence and pave the way for the company’s continued governance and strategic planning for the upcoming year.
For further insights into HK:6990 stock, check out TipRanks’ Stock Analysis page.